Bruno Carlos
Sangro Gómez-Acebo

2024

1. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

   Biomolecules, Vol. 14, Núm. 6

2. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

   JHEP Reports, Vol. 6, Núm. 8

3. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

   Journal of Physiology and Biochemistry

4. Evidence and choice: The BCLC vision for tailoring clinical decision-making

   Journal of Hepatology

5. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

   CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

6. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

   Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457

7. From the Editor's Desk

   Journal of hepatology, Vol. 80, Núm. 2, pp. 173-175

8. From the Editor's Desk.

   Journal of Hepatology

9. From the Editor's Desk.

   Journal of Hepatology

10. From the Editor's Desk...

    Journal of Hepatology

11. From the Editor's Desk...

    Journal of Hepatology

12. From the Editor's Desk...

    Journal of Hepatology

13. From the Editor's Desk...

    Journal of Hepatology

14. From the Editor's Desk…

    Journal of Hepatology

15. From the Editor's Desk…

    Journal of Hepatology

16. From the Editor's Desk…

    Journal of Hepatology

17. Himalaya Overall Survival Prominence and Other Routes to the Peak

    JAMA Oncology

18. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

19. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

20. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432